MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CorMedix Inc

Fermé

SecteurSoins de santé

6.08 -3.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.95

Max

6.31

Chiffres clés

By Trading Economics

Revenu

16M

13M

Ventes

20M

31M

BPA

0.22

Marge bénéficiaire

43.141

Employés

64

EBITDA

16M

14M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+153.97% upside

Dividendes

By Dow Jones

Prochains Résultats

8 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-213M

440M

Ouverture précédente

9.57

Clôture précédente

6.08

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

CorMedix Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2025, 23:04 UTC

Actualités

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 avr. 2025, 22:40 UTC

Principaux Mouvements du Marché

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 avr. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 avr. 2025, 18:51 UTC

Acquisitions, Fusions, Rachats

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 avr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 avr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 avr. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 21:43 UTC

Actualités
Résultats

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 avr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 avr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 avr. 2025, 20:34 UTC

Actualités

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 avr. 2025, 20:23 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 avr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 avr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 avr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 avr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 avr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 avr. 2025, 18:38 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 18:30 UTC

Actualités

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 avr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 avr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 avr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 avr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

CorMedix Inc prévision

Objectif de Prix

By TipRanks

153.97% hausse

Prévisions sur 12 Mois

Moyen 16 USD  153.97%

Haut 20 USD

Bas 12 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

5.94 / 6.64Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.